P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, vol.384, pp.164-172, 2014.

C. Hatzis, R. E. Gould, Y. Zhang, M. Abu-khalaf, G. Chung et al., Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes, Cancer Res, vol.73, pp.6-06, 2013.

W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer et al., Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.25, pp.4414-4422, 2007.

N. M. Hylton, C. A. Gatsonis, M. A. Rosen, C. D. Lehman, D. C. Newitt et al., Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrencefree Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL, Radiology, vol.279, pp.44-55, 2016.

M. Martín, J. I. Chacó-n, A. Antón, A. Plazaola, E. García-martínez et al., Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, 2017.

E. L. Cureton, C. Yau, M. D. Alvarado, H. Krontiras, D. W. Ollila et al., Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/ 150012; ACRIN 6657), Ann Surg Oncol, vol.21, p.24788555, 2014.

J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-angulo, T. A. Buchholz et al., Staging of Breast Cancer in the Neoadjuvant Setting, Cancer Res, vol.68, pp.6477-6481, 2008.

E. A. Mittendorf, J. Vila, S. L. Tucker, M. Chavez-macgregor, B. D. Smith et al., The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment, JAMA Oncol, vol.2, pp.929-936, 2016.

V. Bossuyt, E. Provenzano, W. F. Symmans, J. C. Boughey, C. Coles et al., Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann. Oncol, vol.26, pp.1280-1291, 2015.

A. Hamy, J. Pierga, A. Sabaila, E. Laas, H. Bonsang-kitzis et al., Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer, Ann. Oncol, vol.28, pp.2233-2240, 2017.

J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J. Clin. Oncol, vol.17, pp.1474-1481, 1999.

A. C. Wolff, M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J. Clin. Oncol, vol.25, pp.118-145, 2007.

S. Van-buuren and K. Groothuis-oudshoorn, mice: Multivariate Imputation by Chained Equations in R, Journal of Statistical Software, vol.45, pp.1-67, 2011.

, R Development Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2009.

F. Peintinger, B. Sinn, C. Hatzis, C. Albarracin, E. Downs-kelly et al., Reproducibility of Residual Cancer Burden For Prognostic Assessment of Breast Cancer After Neoadjuvant Chemotherapy, Mod Pathol, vol.28, pp.913-920, 2015.

J. I. Campbell, C. Yau, P. Krass, D. Moore, L. A. Carey et al., Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL, 2017.

, ACRIN 6657), vol.165, pp.181-191

A. Cockburn, J. Yan, D. Rahardja, D. Euhus, Y. Peng et al., Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer, Hum. Pathol, vol.45, pp.249-258, 2014.

A. D. Corben, R. Abi-raad, I. Popa, C. H. Teo, E. A. Macklin et al., Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Comparison Between Classifications and Their Practical Application, Archives of Pathology & Laboratory Medicine, vol.137, pp.1074-1082, 2013.

S. M. Lee, S. K. Bae, T. H. Kim, H. K. Yoon, S. J. Jung et al., Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy, Clin Nucl Med, vol.39, pp.882-886, 2014.

A. Romero, J. A. García-sá-enz, M. Fuentes-ferrer, L. Garcia-asenjo, J. A. Furió et al., Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients, Ann. Oncol, vol.24, pp.655-661, 2013.

A. Sheri, I. E. Smith, S. R. Johnston, R. A'hern, A. Nerurkar et al., Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy, Ann. Oncol, vol.26, pp.75-80, 2015.

W. F. Symmans, C. Wei, R. Gould, X. Yu, Y. Zhang et al., Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype, J. Clin. Oncol, vol.35, pp.1049-1060, 2017.

N. Masuda, S. Lee, S. Ohtani, Y. Im, E. Lee et al., Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy, New England Journal of Medicine, vol.376, pp.2147-2159, 2017.

G. Von-minckwitz, C. Huang, M. S. Mano, S. Loibl, E. P. Mamounas et al., Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N. Engl. J. Med, vol.380, pp.617-628, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02464524

C. Yau, M. Van-der-noordaa, J. Wei, M. Osdoit, F. Reyal et al., Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis, SABCS Abstract, pp.5-6, 2019.

R. Rouzier, C. M. Perou, W. F. Symmans, N. Ibrahim, M. Cristofanilli et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin. Cancer Res, vol.11, pp.5678-5685, 2005.

G. Von-minckwitz, M. Untch, J. Blohmer, S. D. Costa, H. Eidtmann et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol, vol.30, pp.1796-1804, 2012.

W. F. Symmans, C. Hatzis, C. Sotiriou, F. Andre, F. Peintinger et al., Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer, JCO, vol.28, pp.4111-4119, 2010.

A. Hamy, G. Lam, E. Laas, L. Darrigues, T. Balezeau et al., Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma, Breast Cancer Res. Treat, vol.169, p.29374852, 2018.

A. Hamy, H. Bonsang-kitzis, D. D. Croze, E. Laas, L. Darrigues et al., Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy, Clin Cancer Res clincanres, vol.3017, 2018.

L. A. Emens, Breast Cancer Immunotherapy: Facts and Hopes, Clin Cancer Res, vol.24, pp.511-520, 2018.

S. Loi, S. Dushyanthen, P. A. Beavis, R. Salgado, C. Denkert et al., RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors, Clin Cancer Res, vol.22, pp.1499-1509, 2016.

H. L. Mcarthur, A. Diab, D. B. Page, J. Yuan, S. B. Solomon et al., A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling, Clin Cancer Res, vol.22, pp.5729-5737, 2016.

R. Nanda, M. C. Liu, C. Yau, S. Asare, N. Hylton et al., Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2, JCO, vol.35, pp.506-506, 2017.

R. H. Vonderheide, P. M. Lorusso, M. Khalil, E. M. Gartner, D. Khaira et al., Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells, Clin Cancer Res, vol.16, pp.3485-3494, 2010.